BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 71, Issue 9 (September 2019)

Parkinson's Disease: amantadine, zonisamide, dabrafenib Tomoko Okamoto 1 1Department of Neurology, National Institute of Mental Health, National Center of Neurology and Psychiatry Keyword: パーキンソン病 , 治療薬 , アマンタジン , ゾニサミド , ダブラフェニブ , Parkinson's disease , therapeutic agents , amantadine , zonisamide , dabrafenib pp.953-959
Published Date 2019/9/1
  • Abstract
  • Look Inside
  • Reference


Among the therapeutic agents for Parkinson's disease (PD), there are important drugs that precede drug repositioning. Amantadine, developed as a treatment for influenza A, has been long used as a treatment for PD. Zonisamide is an antiepileptic drug developed in Japan, where its therapeutic effects on PD were also discovered and developed. In recent years, dabrafenib, a therapeutic agent for malignant melanoma, has bean identified as a potential therapeutic agent for PD. Amantadine and zonisamide are drugs that have been serendipitously developed in clinical settings for patients with PD. Meanwhile, the potential for repurposing dabrafenib was discovered by utilizing the results of genome-wide association studies, drug databases, and protein-protein interaction databases.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
71巻9号 (2019年9月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院